Home / Learn / Precision Medicine / Treatment / Immunotherapy / Policy & Reimbursement

Policy & Reimbursement

From Oncology Issues

[Publication] Immuno-Oncology in 2020: What We’ve Learned and What Lies Ahead
In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.

Early Identification and Management of Pneumonitis and Other irAEs in Patients with NSCLC
By Sarah Sagorsky, MPAS, PA-C
September 01, 2023
As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.
A New Decade for Advancements in Immunotherapy
June 08, 2023
June is Cancer Immunotherapy Month, and ACCC is highlighting the important work that it and its partners are doing to increase patient access to these novel therapies.